Abstract:Purpose. Human pregnane X receptor (hPXR) has a key role in regulating metabolism of endogenous and exogenous substances. Identification of novel hPXR activators among commercial drugs aids in avoiding drug-drug interactions with future co-administered drugs. Methods. Virtual screening with Structure-Activity Relationship (SAR) models has been applied for identification of novel hPXR activators. Ligand-based modeling was conducted with Discover Studio (DS) 2.1. Bayesian classification models were generated with a training set comprising 177 compound, and were validated with a test set with 145 compounds. The activities of commonly prescribed drugs from SCUT database were predicted with one of the Bayesian models. Cell-based luciferase reporter assay was used for evaluation of chemical-mediated hPXR activation. HepG2 cells were co-transfected with PXR expression vector and CYP2B6-luciferase reporter construct. 0.1% DMSO solution was used as vehicle control while rifampicin as the positive control. The binding mode between an experimental validated hPXR modulators and hPXR were studied by docking a ligand into hPXR binding domain (PDB ID: 1NRL) with programs FlexX and SurFlex. Results. The Bayesian models showed specificity and overall prediction accuracy up to 0.92 and 0.69 for test set compounds. One Bayesian model with specificity of 0.92 was selected to screen the SCUT database and retrieved 113 hits. 17 compounds were chosen for in vitro testing. The luciferase reporter assay confirmed that seven drugs, i.e., fluticasone, nimodipine, nisoldipine, beclomethasone, finasteride, flunisolide, and megestrol were previously unidentified potent or moderate hPXR activators, with 2.7 to 18.5- fold increase in luciferase activity compared to vehicle control. Conclusion. In this study, virtual screening based on SAR models successfully identified seven novel hPXR activators among FDA approved and commonly prescribed drugs. The same approach could be used for identification of activators or inhibitors of other protein targets.

Virtual Screening and Experimental Validation Identify Novel Modulators of Nuclear Receptor RXRα from Drugbank Database.

Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode.

Identification of a New RXRα Antagonist Targeting the Coregulator-Binding Site.

Discovery of Atorvastatin As a Tetramer Stabilizer of Nuclear Receptor RXRα Through Structure-Based Virtual Screening.

Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor

Molecular Recognition of CYP26A1 Binding Pockets and Structure–activity Relationship Studies for Design of Potent and Selective Retinoic Acid Metabolism Blocking Agents

A Structure-based Approach to Retinoid X Receptor-α Inhibition

Binding Characterization, Synthesis and Biological Evaluation of RXRα Antagonists Targeting the Coactivator Binding Site

Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor

Discovery of novel RARα agonists using pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulation studies

In Silico Identification of Small Molecules As Novel LXR Agonists for the Treatment of Cardiovascular Disease and Cancer

Identification of Hpxr Modulators Via Sar-Based Virtual Screening

Structure-based Discovery of New Modulators Targeting Nuclear X Receptor Alpha for Cancer Therapy

Identification of A Novel Partial Agonist of Liver X Receptor Alpha (lxr Alpha) Via Screening

Identification and Validation of Novel Human Pregnane X Receptor Activators among Prescribed Drugs Via Ligand-Based Virtual Screening

Discovery of small molecules from natural compound databases as potent retinoid X alpha receptor agonists to treat Alzheimer's disease

Binding Affinity and Efficacy-Based Pharmacophore Modeling Studies of Retinoic Acid Receptor Alpha Agonists and Virtual Screening for Potential Agonists from NCI

Identification of a Novel Partial Agonist of Liver X Receptor Α (lxrα) Via Screening.

Structure-guided design of a highly potent RXR agonist with superior physicochemical properties

Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics

Structural basis for the full and partial agonist activities of retinoid X receptor α ligands with an iso-butoxy and an isopropyl group